Incidence of Candidemia Is Higher in COVID-19 versus Non-COVID-19 Patients, but Not Driven by Intrahospital Transmission
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
There is scarce information on the actual incidence of candidemia in COVID-19 patients. In addition, comparative studies of candidemia episodes in COVID-19 and non-COVID-19 patients are heterogeneous. Here, we assessed the real incidence, epidemiology, and etiology of candidemia in COVID-19 patients, and compared them with those without COVID-19 (2020 vs. 2019 and 2020, respectively). We also genotyped all C. albicans, C. parapsilosis, and C. tropicalis isolates (n = 88), causing candidemia in both groups, providing for the first time a genotypic characterization of isolates gathered in patients with either COVID-19 or non-COVID-19. Incidence of candidemia was higher in patients with COVID-19 than non-COVID-19 (4.73 vs. 0.85 per 1000 admissions; 3.22 vs. 1.14 per 10,000 days of stay). No substantial intergroup differences were found, including mortality. Genotyping proved the presence of a low number of patients involved in clusters, allowing us to rule out rampant patient-to-patient Candida transmission. The four patients, involved in two clusters, had catheter-related candidemia diagnosed in the first COVID-19 wave, which demonstrates breaches in catheter management policies occurring in such an overwhelming situation. In conclusion, the incidence of candidemia in patients with COVID-19 is significantly higher than in those without COVID-19. However, genotyping shows that this increase is not due to uncontrolled intrahospital transmission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In fact, some studies found higher candidemia incidence among patients with COVID-19 infections compared to those without.36–40”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [39]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rawson, T. M., Moore, L. S. P., Zhu, N., Ranganathan, N., Skolimowska, K., Gilchrist, M., Satta, G., Cooke, G., & Holmes, A. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa530 · Cited by 1,662
Garcia-Vidal, C., Sanjuan, G., Moreno-García, E., Puerta-Alcalde, P., Garcia-Pouton, N., Chumbita, M., Fernandez-Pittol, M., Pitart, C., Inciarte, A., Bodro, M., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.07.041 · Cited by 1,022 · cited 2×
“Unfortunately, studies have been mostly addressed to describe bacterial superinfections [4,5] and Coronavirus-Associated Pulmonary Aspergillosis (CAPA) [6–9].”
BackgroundKoehler, P., Bassetti, M., Chakrabarti, A., Chen, S. C. A., Colombo, A. L., Hoenigl, M., Klimko, N., Lass-Flörl, C., Oladele, R. O., Vinh, D. C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30847-1 · Cited by 951
Song, G., Liang, G., & Liu, W. (2020) · Mycopathologia · doi:10.1007/s11046-020-00462-9 · Cited by 644 · cited 1×
“Previous studies in which Candida genotypi g was carried out are limited by th fact t at the number of isolates was low, they ere sourced exclusiv ly from patients w th COVID-19, and they were not designed to address the question of clonal spreading as a driver of hig er candidemia incidenc in COVID-19 patients [30, 1…”
ResultChanges in the epidemiological landscape of invasive candidiasis
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547
White, P. L., Dhillon, R., Cordey, A., Hughes, H., Faggian, F., Soni, S., Pandey, M., Whitaker, H., May, A., Morgan, M., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1298 · Cited by 445 · cited 1×
“These data reinforce the importance of optimal catheter management to prevent healthcare-associated infections, preestablished diagnostic algorithms, and stewardship programs under current conditions [23,39].”
BackgroundInvasive fungal diseases during COVID-19: We should be prepared
Gangneux, J.-P., Bougnoux, M.-E., Dannaoui, E., Cornet, M., & Zahar, J. R. (2020) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2020.100971 · Cited by 347
Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis
Koehler, P., Stecher, M., Cornely, O. A., Koehler, D., Vehreschild, M. J. G. T., Bohlius, J., Wisplinghoff, H., & Vehreschild, J. J. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.024 · Cited by 336 · cited 3×
“Thirty-day mortality rate of candidemia in tertiary care hospitals has been reported to be around 38% in Europe [48]; in our cohort, the overall mortality rate was 22% (23/103), increasing to 32% in patients with COVID-19.”
BackgroundInfluentialChowdhary, A., Tarai, B., Singh, A., & Sharma, A. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2611.203504 · Cited by 330 · cited 2×
“In the current pandemic situation, an increase in candidemia by multidrug strains such as Candida auris has been reported in some countries, perhaps due to the difficulties in preserving nosocomial infection control programs [17].”
BackgroundBloodstream infections in critically ill patients with COVID‐19
Giacobbe, D. R., Battaglini, D., Ball, L., Brunetti, I., Bruzzone, B., Codda, G., Crea, F., De Maria, A., Dentone, C., Di Biagio, A., et al. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13319 · Cited by 302 · cited 2×
“I ( rti l rl t ri l) r f t t fre e t types of infection in this setting, with a reported incidence rate of 47 episodes (95% confide ce interval (CI) 35–63) per 1000 patient-days at risk [33].”
BackgroundNori, P., Cowman, K., Chen, V., Bartash, R., Szymczak, W., Madaline, T., Punjabi Katiyar, C., Jain, R., Aldrich, M., Weston, G., et al. (2021) · Infection Control & Hospital Epidemiology · doi:10.1017/ice.2020.368 · Cited by 290
Arastehfar, A., Carvalho, A., Nguyen, M. H., Hedayati, M. T., Netea, M. G., Perlin, D. S., & Hoenigl, M. (2020) · Journal of Fungi · doi:10.3390/jof6040211 · Cited by 272
COVID-19–Associated Pulmonary Aspergillosis, March–August 2020
Salmanton-García, J., Sprute, R., Stemler, J., Bartoletti, M., Dupont, D., Valerio, M., Garcia-Vidal, C., Falces-Romero, I., Machado, M., de la Villa, S., et al. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2704.204895 · Cited by 269
Self-citationArendrup, M. C., Friberg, N., Mares, M., Kahlmeter, G., Meletiadis, J., Guinea, J., Arendrup, M. C., Meletiadis, J., Guinea, J., Friberg, N., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.06.007 · Cited by 238
Self-citationInvasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity
Machado, M., Valerio, M., Álvarez‐Uría, A., Olmedo, M., Veintimilla, C., Padilla, B., De la Villa, S., Guinea, J., Escribano, P., Ruiz‐Serrano, M. J., et al. (2021) · Mycoses · doi:10.1111/myc.13213 · Cited by 203
Self-citationIncreased incidence of candidemia in a tertiary care hospital with the COVID‐19 pandemic
Nucci, M., Barreiros, G., Guimarães, L. F., Deriquehem, V. A. S., Castiñeiras, A. C., & Nouér, S. A. (2021) · Mycoses · doi:10.1111/myc.13225 · Cited by 193 · cited 1×
“However, the authors also suggested that this increase may be due to a reduction in admissions [14].”
BackgroundTocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
Antinori, S., Bonazzetti, C., Gubertini, G., Capetti, A., Pagani, C., Morena, V., Rimoldi, S., Galimberti, L., Sarzi-Puttini, P., & Ridolfo, A. L. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102564 · Cited by 183
The Landscape of Candidemia During the Coronavirus Disease 2019 (COVID-19) Pandemic
Seagle, E. E., Jackson, B. R., Lockhart, S. R., Georgacopoulos, O., Nunnally, N. S., Roland, J., Barter, D. M., Johnston, H. L., Czaja, C. A., Kayalioglu, H., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab562 · Cited by 141
Bacterial and fungal superinfections in critically ill patients with COVID-19
Bassetti, M., Kollef, M. H., & Timsit, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06219-8 · Cited by 139 · cited 1×
“Unfortunately, studies have been mostly addressed to describe bacterial superinfections [4,5] and Coronavirus-Associated Pulmonary Aspergillosis (CAPA) [6–9].”
BackgroundIbrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
Jallow, S., & Govender, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7030163 · Cited by 129
Kayaaslan, B., Eser, F., Kaya Kalem, A., Bilgic, Z., Asilturk, D., Hasanoglu, I., Ayhan, M., Tezer Tekce, Y., Erdem, D., Turan, S., et al. (2021) · Mycoses · doi:10.1111/myc.13332 · Cited by 126 · cited 1×
“, use of corticosteroids or antimicrobial agents, or the detrimental stewardship of central venous catheter (CVC) care during the pandemic [17,20,22,23].”
BackgroundMastrangelo, A., Germinario, B. N., Ferrante, M., Frangi, C., Li Voti, R., Muccini, C., Ripa, M., COVID-BioB Study Group, Canetti, D., Castiglioni, B., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1594 · Cited by 112
Arastehfar, A., Daneshnia, F., Hilmioğlu-Polat, S., Fang, W., Yaşar, M., Polat, F., Metin, D. Y., Rigole, P., Coenye, T., Ilkit, M., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01001-20 · Cited by 110 · cited 1×
“parapsilosis isolates have been reported in different hospitals [44].”
BackgroundIs the Frequency of Candidemia Increasing in COVID-19 Patients Receiving Corticosteroids?
Riche, C. V. W., Cassol, R., & Pasqualotto, A. C. (2020) · Journal of Fungi · doi:10.3390/jof6040286 · Cited by 103
Friedrich, R., Rappold, E., Bogdan, C., & Held, J. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00464-18 · Cited by 81 · cited 1×
“5%, respectively) [46]; these data are in line with our observations of lower sensitivity values using the Wako test (93.”
ResultCandidemia among Iranian Patients with Severe COVID-19 Admitted to ICUs
Arastehfar, A., Shaban, T., Zarrinfar, H., Roudbary, M., Ghazanfari, M., Hedayati, M.-T., Sedaghat, A., Ilkit, M., Najafzadeh, M. J., & Perlin, D. S. (2021) · Journal of Fungi · doi:10.3390/jof7040280 · Cited by 81
Rajni, E., Singh, A., Tarai, B., Jain, K., Shankar, R., Pawar, K., Mamoria, V., & Chowdhary, A. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab452 · Cited by 81 · cited 1×
“Previous studies in which Candida genotyping was carried out are limited by the fact that the number of isolates was low, they were sourced exclusively from patients with COVID-19, and they were not designed to address the question of clonal spreading as a driver of higher candidemia incidence in COVID-19 patients [30…”
ResultMacauley, P., & Epelbaum, O. (2021) · Mycoses · doi:10.1111/myc.13258 · Cited by 78 · cited 1×
“These findings were not confirmed in a USA tertiary care center analyzing ICU patients with and without COVID-19 infection [19].”
ResultICU-acquired bloodstream infections in critically ill patients with COVID-19
Kokkoris, S., Papachatzakis, I., Gavrielatou, E., Ntaidou, T. K., Ischaki, E., Malachias, S., Vrettou, C. S., Nichlos, C., Kanavou, A., Zervakis, D. I., et al. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.11.009 · Cited by 74 · cited 1×
“2%) [36], possibly due to the increased use of antibiotics and the consequent impact on gut microbiome composition.”
BackgroundFungemia in COVID‐19 ICU patients, a single medical center experience
Bishburg, E., Okoh, A., Nagarakanti, S. R., Lindner, M., Migliore, C., & Patel, P. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26633 · Cited by 70
Recommendations for the use of vascular access in the COVID-19 patients: an Italian perspective
on behalf of the GAVeCeLT Working Group for Vascular Access in COVID-19, Pittiruti, M., & Pinelli, F. (2020) · Critical Care · doi:10.1186/s13054-020-02997-1 · Cited by 67
Pérez-Granda, M. J., Sánchez‐Carrillo, C., Rabadán, P. M., Valerio, M., Olmedo, M., Muñóz, P., & Bouza, E. (2021) · Journal of Hospital Infection · doi:10.1016/j.jhin.2021.09.020 · Cited by 66
Self-citationGuisado-Gil, A. B., Infante-Domínguez, C., Peñalva, G., Praena, J., Roca-Oporto, C., Navarro-Amuedo, M. D., Aguilar‐Guisado, M., Aguilera, N. E., Borrego, M. P., Romero-Rodríguez, N., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9110816 · Cited by 64 · cited 2×
“, use of corticosteroids or antimicrobial agents, or the detrimental stewardship of central venous catheter (CVC) care during the pandemic [17,20,22,23].”
BackgroundCarolis, E. D., Marchionni, F., Torelli, R., Morandotti, G. A., Pagano, L., Murri, R., PASCALE, G. D., Angelis, G. D., Sanguinetti, M., & Posteraro, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236095 · Cited by 54 · cited 1×
“Using the optimal cutoff level of 7 pg/mL in the Wako test, as recommended by some authors [29], the sensitivity increased to 78% (32/41).”
Methodon behalf of the COMIC Study Group (Collaborative Group on Mycosis), Agnelli, C., Valerio, M., Bouza, E., Vena, A., Guinea, J., Martínez‐Jiménez, M. D. C., Marcos-Zambrano, L. J., Escribano, P., & Muñóz, P. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03477-3 · Cited by 51 · cited 1×
“Persistent candidemia was defined as one or more positive follow-up BCs obtained ≥ 5 days from incident BCs in patients receiving antifungal therapy [24].”
BackgroundSelf-citationDíaz-García, J., Mesquida, A., Sánchez-Carrillo, C., Reigadas, E., Muñoz, P., Escribano, P., & Guinea, J. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01827-20 · Cited by 39
Self-citationGuinea, J., Arendrup, M. C., Cantón, R., Cantón, E., García‐Rodríguez, J., Gómez, A., de la Pedrosa, E. G. G., Hare, R. K., Orden, B., Sanguinetti, M., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00166 · Cited by 34 · cited 3×
“Species-specific microsatellite markers were used to genotype C. albicans (CDC3, EF3, HIS3 CAI, CAIII, and CAVI), C. parapsilosis (CP1, CP4a, CP6, and B), and C. tropicalis (Ctrm1, Ctrm10, Ctrm12, Ctrm21, Ctrm24, and Ctrm28) [28].”
MethodInfluentialSelf-citationMesquida, A., Díaz-García, J., Sánchez‐Carrillo, C., Muñóz, P., Escribano, P., & Guinea, J. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.030 · Cited by 31 · cited 2×
“Since there are no available clinical breakpoints for isavuconazole and ibrexafungerp, we used previously proposed tentative ECOFFs or wild-type upper limits [26,27].”
MethodResultSelf-citationAgnelli, C., Bouza, E., Martínez‐Jiménez, M. D. C., Navarro, R., Valerio, M., Machado, M., Guinea, J., Sánchez‐Carrillo, C., Alonso, R., & Muñóz, P. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz555 · Cited by 29
Self-citationDíaz-García, J., Mesquida, A., Gómez, A., Machado, M., Martín‐Rabadán, P., Alcalá, L., Sánchez‐Carrillo, C., Reigadas, E., Vicente, T., Muñoz, P., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01249-21 · Cited by 29 · cited 1×
“We found an echinocandin-resistant isolate from a patient with COVID-19 who had received anidulafungin; previous use of echinocandins may promote echinocandin resistance, as reported in a series of patients in our own hospital [41].”
BackgroundSelf-citationCOVID-19 and invasive fungal coinfections: A case series at a Brazilian referral hospital
Martins, A. C., Psaltikidis, E. M., de Lima, T. C., Fagnani, R., Schreiber, A. Z., Conterno, L. D. O., Kamei, K., Watanabe, A., Trabasso, P., Resende, M. R., et al. (2021) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2021.101175 · Cited by 28
Ramos, R., de la Villa, S., García-Ramos, S., Padilla, B., García-Olivares, P., Piñero, P., Garrido, A., Hortal, J., Muñóz, P., Caamaño, E., et al. (2021) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2021.10.014 · Cited by 28
Self-citationIsavuconazole is highly active in vitro against Candida species isolates but shows trailing effect
Marcos-Zambrano, L. J., Gómez, A., Sánchez‐Carrillo, C., Bouza, E., Muñóz, P., Escribano, P., & Guinea, J. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.07.006 · Cited by 25 · cited 1×
“Since there are no available clinical breakpoints for isavuconazole and ibrexafungerp, we used previously proposed tentative ECOFFs or wild-type upper limits [26,27].”
MethodSelf-citationEscribano, P., Sánchez‐Carrillo, C., Muñóz, P., Bouza, E., & Guinea, J. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00574-18 · Cited by 23 · cited 1×
“In a previous publication, we reported the presence of a high number of clusters in patients admitted at the hospital between 2007 and 2010; after that period, a campaign to promote awareness on catheterrelated infection was started, with a consequent reduction in clusters [45].”
BackgroundSelf-citationCOVID-19 and Candida duobushaemulonii superinfection: A case report
Awada, B., Alam, W., Chalfoun, M., Araj, G. F., & Bizri, A. R. (2021) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2021.101168 · Cited by 17
Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect
Marcos-Zambrano, L. J., Gómez, A., Sánchez‐Carrillo, C., Bouza, E., Muñóz, P., Escribano, P., & Guinea, J. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.07.023 · Cited by 17
Self-citationKordalewska, M., Guerrero, K. D., Garcia‐Rubio, R., Jiménez‐Ortigosa, C., Mediavilla, J. R., Cunningham, M. H., Hollis, F., Hong, T., Chow, K. F., Kreiswirth, B. N., et al. (2021) · Journal of Fungi · doi:10.3390/jof7070552 · Cited by 13 · cited 2×
“Previous studies in which Candida genotypi g was carried out are limited by th fact t at the number of isolates was low, they ere sourced exclusiv ly from patients w th COVID-19, and they were not designed to address the question of clonal spreading as a driver of hig er candidemia incidenc in COVID-19 patients [30, 1…”
ResultCoronavirus disease and candidemia infection: A case report
Görkem, A., Sav, H., Kaan, Ö., & EREN, E. E. (2021) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2021.101155 · Cited by 12
Alataby, H., Atemnkeng, F. N., Bains, S. S., Kenne, F. M., Diaz, K. T., & Nfonoyim, J. M. (2020) · Journal of Medical Cases · doi:10.14740/jmc3588 · Cited by 10
Research works printed but not linked: 1
- Mastrangelo, 2020, Candidemia in COVID-19 patients: Incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls, Clin. Infect. Dis., 30, ciaa1594
Cited by
Candida albicans and Candida glabrata : global priority pathogens
Katsipoulaki, M., Stappers, M. H. T., Malavia-Jones, D., Brunke, S., Hube, B., & Gow, N. A. R. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00021-23 · Cited by 180
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
Candidiasis and Other Emerging Yeasts
Sharma, M., & Chakrabarti, A. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00455-3 · Cited by 123
“parapsilosis to fluconazole and voriconazole during COVID-19 pandemic [79, 80].”
Candida parapsilosis complex in the clinical setting
Govrins, M. A., & Lass‐Flörl, C. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00961-8 · Cited by 94
“Firstly, COVID-19-associated candidiasis cases in patients who are critically ill increased significantly 41,42 , with candidaemia occurring at a two to ten times higher rate than that reported in historical populations without COVID-19 (ref.”
BackgroundFluconazole-resistant Candida parapsilosis: A new emerging threat in the fungi arena
Escribano, P., & Guinea, J. (2022) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2022.1010782 · Cited by 74
“Inour hospital,whereas the incidence of candidaemiawas higher in patients with COVID-19 than without, genotyping demonstrated that the increasewasnot due touncontrolled intra-hospital patientto-patient transmission (Machado et al., 2022).”
BackgroundSelf-citation
Metadata
- Authors
- Machado, M., Estévez, A., Sánchez-Carrillo, C., Guinea, J., Escribano, P., Alonso, R., Valerio, M., Padilla, B., Bouza, E., & Muñoz, P.
- Affiliations
- Hospital General Universitario Gregorio Marañón (ES)
- Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Machado, Marina
- Estévez, Agustín
- ORCID
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2022-03-16
- Volume
- 8
- Issue
- 3
- Pages
- 305
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC8950429
- OpenAlex
- W4221131994
- Cited by
- 53
- References
- 50
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 11 · 2023: 18 · 2022: 11
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Docta Complutense (Universidad Complutense de Madrid) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Instituto de Salud Carlos III (PI18/01155, PI19/00074, PI20/00575)
- European Regional Development Fund (ERDF) (N/A)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, COVID-19 pandemic, Candida albicans, Candida parapsilosis, Candida tropicalis, candidemia incidence, genotyping, catheter-related candidemia, central venous catheters, infection clusters, mortality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.